CN1850191A - Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method - Google Patents
Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method Download PDFInfo
- Publication number
- CN1850191A CN1850191A CN 200610057187 CN200610057187A CN1850191A CN 1850191 A CN1850191 A CN 1850191A CN 200610057187 CN200610057187 CN 200610057187 CN 200610057187 A CN200610057187 A CN 200610057187A CN 1850191 A CN1850191 A CN 1850191A
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- radix scutellariae
- fructus gardeniae
- herba artemisiae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 31
- 229940012356 eye drops Drugs 0.000 title claims abstract description 13
- 244000111489 Gardenia augusta Species 0.000 title claims description 13
- 235000018958 Gardenia augusta Nutrition 0.000 title claims description 13
- 235000008658 Artemisia capillaris Nutrition 0.000 title claims description 12
- 241000092668 Artemisia capillaris Species 0.000 title claims description 12
- 235000017089 Scutellaria baicalensis Nutrition 0.000 title claims description 12
- 240000004534 Scutellaria baicalensis Species 0.000 title claims description 12
- 238000000034 method Methods 0.000 title description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 206010010741 Conjunctivitis Diseases 0.000 claims abstract description 14
- 241000245240 Lonicera Species 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims abstract 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 241000628997 Flos Species 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 13
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 13
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 13
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 239000000835 fiber Substances 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 238000005374 membrane filtration Methods 0.000 claims description 9
- 239000008215 water for injection Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000012489 doughnuts Nutrition 0.000 claims 1
- 229920002492 poly(sulfone) Polymers 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 201000007032 bacterial conjunctivitis Diseases 0.000 abstract description 11
- 206010023332 keratitis Diseases 0.000 abstract description 8
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 abstract description 6
- 201000005547 chronic conjunctivitis Diseases 0.000 abstract description 3
- 206010010755 Conjunctivitis viral Diseases 0.000 abstract description 2
- 208000005914 Viral Conjunctivitis Diseases 0.000 abstract description 2
- 240000001972 Gardenia jasminoides Species 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 7
- 229960003321 baicalin Drugs 0.000 description 7
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 201000004484 acute conjunctivitis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- -1 filters Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- KIZFHUJKFSNWKO-UHFFFAOYSA-M calcium monohydroxide Chemical compound [Ca]O KIZFHUJKFSNWKO-UHFFFAOYSA-M 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012991 xanthate Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Yizhihuang eye drops and its preparation method. It can be used for curing the diseases of conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, acute hemorrhagic conjunctivitis, neonatal bacterial conjunctivitis and chronic conjunctivitis and keratitis, etc. It is made up by using four Chinese medicinal materials of lonicera flower, scutellaria root, capillaries and gardenia fruit through a certain preparation process.
Description
Technical field
The present invention relates to a kind of mattress Cape jasmine xanthate thing preparation, particularly eye drops with capillary artemisia, cape jasmine and baikal skullcap root, said preparation can be used for the treatment of conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, acute hemorrhagic conjunctivitis, neonate bacterial conjunctivitis and chronic knot keratitis etc.
Background technology
Conjunctivitis is the commonly encountered diseases and the frequently-occurring disease of ophthalmology, and bacillary, viral, clothing body and immune-related conjunctivitis etc. are arranged.Wherein, acute hemorrhagic conjunctivitis is due to the viral infection, and morbidity is anxious, and infectiousness is extremely strong, and sickness rate often causes large tracts of land crowd outbreak of epidemic up to 7.45%, is being come the 7th of 10 big infectious disease rankings.In case eruption and prevalence is often brought heavy losses to the healthy of people and work life.
The treatment of conjunctivitis is how with the treatment of chemical drugss such as antibiotic, antiviral, the problem of ubiquity abuse of antibiotics clinically, thereby, caused the side effect that Resistant strain is on the increase to be increased with untoward reaction.And to a line medication of bacterial conjunctivitis in the past, as chloromycetin and the then most drug resistances of rifampicin; The sickness rate of chronic conjunctivitis accounts for the first place of ophthalmology various diseases, at present, does not still have the specific drug treatment; Viral acute hemorrhagic conjunctivitis antibiotic is generally invalid, and the antiviral eye drop has certain curative effect, but the same with antibiotic, and its drug resistance and untoward reaction is in various degree all arranged.
The present invention is to be guidance with the Chinese medicine traditional theory, heat-clearing and toxic substances removing, the function of gallbladder promoting that will have broad-spectrum antiseptic, antivirus action protect the liver the dialectical combination of Chinese medicine Flos Lonicerae, Radix Scutellariae, Herba Artemisiae Scopariae and Fructus Gardeniae, other wards off the new clinical indication of treatment conjunctivitis, and especially the acute hemorrhagic conjunctivitis to viral infection has definite curative effect.New drug process using nanometer film isolation technics, the impurity of molecular weight more than 30000～50000 that dams makes new drug preparation purity height, and clarity is good, eye conjunctiva degree of absorbing height, patient is easy to accept.Compare with antibiotic, antiviral chemical drugs, determined curative effect has no side effect.For ophthalmology common disease, frequently-occurring disease have increased a kind of new effective, nontoxic medicine.
Summary of the invention
The invention provides a kind of eye drops with capillary artemisia, cape jasmine and baikal skullcap root, this eye drop is formed through extracting processing and preparing by Chinese crude drugs such as Herba Artemisiae Scopariae, Fructus Gardeniae, Radix Scutellariae, Flos Loniceraes.
Eye drop of the present invention, the prescription of its active component is as follows:
Herba Artemisiae Scopariae extract 3.0-12.0g, Fructus Gardeniae extract 1.6-6.4g, Radix Scutellariae extract 11.0-44.0g, Flos Lonicerae extract 11.0-44.0g.
Preferred prescription is as follows: Herba Artemisiae Scopariae extract 4.8g, Fructus Gardeniae extract 2.6g, Radix Scutellariae extract 17.6g, Flos Lonicerae extract 17.6g, sodium chloride 4.0g, ethylparaben 2.4g.
Eye drop of the present invention also can add osmotic pressure regulator in case of necessity, adjuvants such as solubilizing agent and pH regulator agent.Described osmotic pressure regulator is selected from sodium chloride, glucose, dextran etc.; Solubilizing agent is selected from tween 80; The pH regulator agent is selected from sodium hydroxide, hydrochloric acid etc.
The preferred prescription of eye drop of the present invention is composed as follows: Herba Artemisiae Scopariae extract 4.8g, Fructus Gardeniae extract 2.6g, Radix Scutellariae extract 17.6g, Flos Lonicerae extract 17.6g, sodium chloride 4.0g, ethylparaben 2.4g, water for injection, this prescription can prepare eye drop 1000ml.
Preparation method is as follows: above Chinese medicine extract four flavors, getting Radix Scutellariae extract, to add hot water an amount of, with the sodium hydroxide solution adjust pH to dissolving; Herba Artemisiae Scopariae extract, Fructus Gardeniae extract, Flos Lonicerae extract are dissolved in water respectively, and sodium chloride, ethylparaben add the hot water dissolving in addition, and mixing is regulated pH value.Water for injection is diluted to 1000ml, with the hollow-fibre membrane filtration in molecular cut off 30000 apertures, fill, sterilization, promptly.
Preferred manufacturing procedure is as follows: above Chinese medicine extract four flavors, getting Radix Scutellariae extract, to add hot water an amount of, with the sodium hydroxide solution adjust pH to dissolving; Herba Artemisiae Scopariae extract, Fructus Gardeniae extract, Flos Lonicerae extract are dissolved in water respectively, and sodium chloride, ethylparaben add the hot water dissolving in addition, and mixing is regulated pH value.Water for injection is diluted to 1000ml, with the hollow-fibre membrane filtration in molecular cut off 30000 apertures, fill, sterilization, promptly.
Eye drop of the present invention, active component wherein is a Chinese medicine extract, described Chinese medicine extract as: Herba Artemisiae Scopariae extract, Fructus Gardeniae extract, Radix Scutellariae extract, Flos Lonicerae extract are the effective site goods that meet drug standard, list " Chinese pharmacopoeia or other documents in, they can have been bought from the market, also can prepare according to known technology, following preparation method can be utilized:
(1) Herba Artemisiae Scopariae extract is got Herba Artemisiae Scopariae, makes solvent by the percolation percolation with 15 times of amount 90% ethanol.Merge percolate, remove grease such as chlorophyll, with the hollow-fibre membrane filtration in molecular cut off 30000 apertures.Filtrate was concentrated into relative density 1: 1.30 (70 ℃), made extract through drying under reduced pressure.
(2) Fructus Gardeniae extract is got Fructus Gardeniae, adds 70% alcohol reflux three times of 8 times of amounts, and each 40 minutes, merge the backflow medicinal liquid, filter with the hollow-fibre membrane in molecular cut off 30000 apertures.Filtrate was concentrated into relative density 1: 1.30 (70 ℃), made extract through drying under reduced pressure.
(3) preparation of Radix Scutellariae extract decocts with water secondary with Radix Scutellariae, and each 1 hour, filter, merging filtrate is regulated pH value to 1.0-2.0 with hydrochloric acid, and 80 ℃ of insulations are left standstill, and the baicalin cohesion is separated out, and filter.Discard filtrate, precipitate adds suitable quantity of water and stirs evenly, and with 40% sodium hydroxide solution adjust pH to 7.0, adds equivalent ethanol, stirs the companion and makes dissolving, filters.Filtrate is regulated pH value to 1.0-2.0 with hydrochloric acid, is heated to 60 ℃, leaves standstill, and baicalin is separated out, and filters.Precipitation is washed till pH value to 7.0 with suitable quantity of water and Different concentrations of alcohol successively, waves most ethanol, drying under reduced pressure, promptly.This product contains baicalin should be not less than 85.0%.
(4) preparation of Flos Lonicerae extract decocts with water secondary with Flos Lonicerae, and 1 hour for the first time, 45 minutes for the second time, gradation filtered.Merging filtrate is evaporated to every ml and is equivalent to Flos Lonicerae 2g, adds 20% lime cream (CaOH), regulates pH value to 12 and stirs evenly, and leaves standstill 12 hours.Filter, discard filtrate, precipitation adds 2 times of amount ethanol and stirs evenly, and crosses sieve No. 4, regulates pH value to 3 with 50% sulfuric acid solution, fully stirs evenly, and filters.Filtrate is neutralized to pH6.5 with 40% sodium hydroxide solution, filters, and filtrate decompression is condensed into the thick paste shape, drying, promptly.This product contains chlorogenic acid should be not less than 18%.
Eye drop of the present invention can be treated conjunctivitis, and especially the acute hemorrhagic conjunctivitis to viral infection has definite curative effect.Eye drop process using nanometer film isolation technics of the present invention, the impurity of molecular cut off more than 30000～50000 makes new drug preparation purity height, and clarity is good, eye conjunctiva degree of absorbing height, patient is easy to accept.Compare with antibiotic, antiviral chemical drugs, determined curative effect has no side effect.Preferably fill a prescription to form and have excellent especially treatment for ophthalmology common disease, frequently-occurring disease have increased a kind of new effective, nontoxic medicine, particularly the present invention, stable, nontoxic effect.
The specific embodiment
Further specify the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1
Herba Artemisiae Scopariae extract is got Herba Artemisiae Scopariae, makes solvent by the percolation percolation with 15 times of amount 90% ethanol.Merge percolate, remove grease such as chlorophyll, with the hollow-fibre membrane filtration in molecular cut off 30000 apertures.Filtrate was concentrated into relative density 1: 1.30 (70 ℃), made extract through drying under reduced pressure.
Embodiment 2
Fructus Gardeniae extract is got Fructus Gardeniae, adds 70% alcohol reflux three times of 8 times of amounts, and each 40 minutes, merge the backflow medicinal liquid, filter with the hollow-fibre membrane in molecular cut off 30000 apertures.Filtrate was concentrated into relative density 1: 1.30 (70 ℃), made extract through drying under reduced pressure.
Embodiment 3
The preparation of Radix Scutellariae extract decocts with water secondary with Radix Scutellariae, and each 1 hour, filter, merging filtrate is regulated pH value to 1.0-2.0 with hydrochloric acid, and 80 ℃ of insulations are left standstill, and the baicalin cohesion is separated out, and filter.Discard filtrate, precipitate adds suitable quantity of water and stirs evenly, and with 40% sodium hydroxide solution adjust pH to 7.0, adds equivalent ethanol, stirs the companion and makes dissolving, filters.Filtrate is regulated pH value to 1.0-2.0 with hydrochloric acid, is heated to 60 ℃, leaves standstill, and baicalin is separated out, and filters.Precipitation is washed till pH value to 7.0 with suitable quantity of water and Different concentrations of alcohol successively, waves most ethanol, drying under reduced pressure, promptly.This product contains baicalin should be not less than 85.0%.
Embodiment 4
The preparation of Flos Lonicerae extract decocts with water secondary with Flos Lonicerae, and 1 hour for the first time, 45 minutes for the second time, gradation filtered.Merging filtrate is evaporated to every ml and is equivalent to Flos Lonicerae 2g, adds 20% lime cream (Ca (OH)
2), regulate pH value to 12 and stir evenly, left standstill 12 hours.Filter, discard filtrate, precipitation adds 2 times of amount ethanol and stirs evenly, and crosses sieve No. 4, regulates pH value to 3 with 50% sulfuric acid solution, fully stirs evenly, and filters.Filtrate is neutralized to pH6.5 with 40% sodium hydroxide solution, filters, and filtrate decompression is condensed into the thick paste shape, drying, promptly.This product contains chlorogenic acid should be not less than 18%.
Embodiment 5
Prescription: Herba Artemisiae Scopariae extract 4.8g, Fructus Gardeniae extract 2.6g, Radix Scutellariae extract 17.6g, Flos Lonicerae extract 17.6g, sodium chloride 4g, ethylparaben 3g.
Preparation method: with four flavors on the Chinese medicine extract, getting Radix Scutellariae extract, to add hot water an amount of, with the sodium hydroxide solution adjust pH to dissolving; Herba Artemisiae Scopariae extract, Fructus Gardeniae extract, Flos Lonicerae extract are dissolved in water respectively, and sodium chloride, ethylparaben add the hot water dissolving in addition, and mixing is regulated pH value.Water for injection is diluted to 1000ml, with the hollow-fibre membrane filtration in molecular cut off 30000 apertures, fill, sterilization, promptly.
Embodiment 6
Prescription: Herba Artemisiae Scopariae extract 2.4g, Fructus Gardeniae extract 1.3g, Radix Scutellariae extract 8.8g, Flos Lonicerae extract 8.8g, sodium chloride 4g, ethylparaben 5g.
Preparation method: above four flavors, getting Radix Scutellariae extract, to add hot water an amount of, with the sodium hydroxide solution adjust pH to dissolving; Herba Artemisiae Scopariae extract, Fructus Gardeniae extract, Flos Lonicerae extract are dissolved in water respectively, and sodium chloride, ethylparaben add the hot water dissolving in addition, and mixing is regulated pH value.Water for injection is diluted to 1000ml, with the hollow-fibre membrane filtration in molecular cut off 30000 apertures, fill, sterilization, promptly.
Embodiment 7
Prescription: Herba Artemisiae Scopariae extract 9.6g, Fructus Gardeniae extract 5.1g, baicalin extract 35.2g, Flos Lonicerae extract 35.2g, sodium chloride 4g, ethylparaben 4g.
Preparation method: above Chinese medicine extract four flavors, getting Radix Scutellariae extract, to add hot water an amount of, with the sodium hydroxide solution adjust pH to dissolving; Herba Artemisiae Scopariae extract, Fructus Gardeniae extract, Flos Lonicerae extract are dissolved in water respectively, and sodium chloride, ethylparaben add the hot water dissolving in addition, and mixing is regulated pH value.Water for injection is diluted to 1000ml, with the hollow-fibre membrane filtration in molecular cut off 30000 apertures, fill, sterilization, promptly.
Clinical practice
Acute bacterial conjunctivitis and epizootic disease toxicity knot keratitis belong to the traditional Chinese medical science " acute conjunctivitis ", " acute and chronic conjunctivitis " category, and the former is the commonly encountered diseases of ophthalmology, and the latter is the normal epidemic diseases of sending out of ophthalmology.Treat primary disease with eye drops with capillary artemisia, cape jasmine and baikal skullcap root, effect is remarkable, is supervision, side effect.
1 clinical data
Select acute bacterial conjunctivitis, epizootic disease toxicity knot keratitis patient 105 examples, be divided into treatment group 75 example and matched group 30 examples at random.147 eyes of 75 examples, male 41 examples, women 34 examples are organized in treatment.Minimum 12 years old of age, maximum 72 years old.57 eyes of matched group 35 examples, male 17 examples, women 13 examples.Minimum 13 years old of age, maximum 65 years old.Two groups of the shortest 1d of the course of disease, the longest 5d, routine number is similar, and sex, age are suitable, there was no significant difference between group (P＞0.05).
2 Therapeutic Method
Treatment group eye drops with capillary artemisia, cape jasmine and baikal skullcap root, 6 times on the 1st, each 2.Matched group acute bacterial conjunctivitis rifampicin eye drop, 1 day 6, each 2.Epizootic disease toxicity knot keratitis aciclovir eye drop, 6 times on the 1st, each 2.Two groups the course of treatment acute bacterial conjunctivitis 5d, epidemic virus membranous conjunctivitis 7d is with keratitis person 14d.As a result, use x
2Check.
3 therapeutic outcomes
3.1 the acute bacterial conjunctivitis curative effect is 72 eyes of eye drops with capillary artemisia, cape jasmine and baikal skullcap root treatment group relatively, fully recover 53 (73.6%) 15 of produce effects (20.8%), effective 3 (4.2%), invalid 1.Total effective rate 98.6%; 26 eyes of matched group are fully recovered 6 (23.1%), 10 of produce effects (38.4%), effective 8 (30.8%), invalid 2 (7.7%), 92.3%%, two group of invalid significance of difference of total effective rate (P＞0 05); And total obvious effective rate eye drops with capillary artemisia, cape jasmine and baikal skullcap root treatment group 94.4%, matched group has significant difference (P＜001) for 61.5%, two group.
42 epizootic disease toxicity knot keratitis curative effect is 75 eyes of eye drops with capillary artemisia, cape jasmine and baikal skullcap root treatment group relatively, fully recover 47 (62.7%) 21 of produce effects (28.0%), effective 6 (8.0%), invalid 1, total effective rate 98.7%, total obvious effective rate 90.7%.31 eyes of matched group are fully recovered 8 (25.8%), 8 of produce effects (25.8%), effective 14 (45.2%), invalid 1.Total effective rate 96.8%, total obvious effective rate 516%.Two groups are relatively, total effective rate difference with insignificance (P＞0 05), and total obvious effective rate has utmost point significant difference (P＜0 01).
Clinical effectiveness shows that eye drops with capillary artemisia, cape jasmine and baikal skullcap root all has significant curative effect to acute bacterial conjunctivitis and epizootic disease toxicity knot keratitis, and, do not find untoward reaction in the treatment.
Claims (9)
1, a kind of eye drops with capillary artemisia, cape jasmine and baikal skullcap root is characterized in that, becomes preparation by Chinese crude drugs such as Herba Artemisiae Scopariae, Fructus Gardeniae, Radix Scutellariae, Flos Loniceraes through extracting processing and preparing.
2, the eye drop of claim 1, the prescription of active component is as follows: Herba Artemisiae Scopariae extract 3.0-12.0g, Fructus Gardeniae extract 1.6-6.4g, Radix Scutellariae extract 11.0-44.0g, Flos Lonicerae extract 11.0-44.0g.
3, the eye drop of claim 1, the prescription of active component is as follows: Herba Artemisiae Scopariae extract 6.0g, Fructus Gardeniae extract 3.2g, Radix Scutellariae extract 22.0g, Flos Lonicerae extract 22.0g.
4, the eye drop of claim 1, the prescription of preparation is composed as follows: Herba Artemisiae Scopariae extract 3.0-12.0g, Fructus Gardeniae extract 1.6-6.4g, Radix Scutellariae extract 11.0-44.0g, Flos Lonicerae extract 11.0-44.0g, sodium chloride 3.5-4.5g, ethylparaben 3g.
5, the eye drop of claim 1, the prescription of preparation is composed as follows: Herba Artemisiae Scopariae extract 4.8g, Fructus Gardeniae extract 2.6g, Radix Scutellariae extract 17.6g, Flos Lonicerae extract 17.6g, sodium chloride 4.0g, ethylparaben 2.4g.
6, the preparation method of the eye drop of claim 1 is characterized in that, through following steps: getting Radix Scutellariae extract, to add hot water an amount of, with the sodium hydroxide solution adjust pH to dissolving; Herba Artemisiae Scopariae extract, Fructus Gardeniae extract, Flos Lonicerae extract are dissolved in water respectively, and other gets adjuvant, and mixing is regulated pH value to 6.6-7.8, and water for injection is diluted to 1000ml, with the hollow-fibre membrane filtration in molecular cut off 30000 apertures, fill, sterilization, promptly.
7, the preparation method of the eye drop of claim 1 is characterized in that, through following steps: getting Radix Scutellariae extract, to add hot water an amount of, with the sodium hydroxide solution adjust pH to dissolving; Herba Artemisiae Scopariae extract, Fructus Gardeniae extract, Flos Lonicerae extract are dissolved in water respectively, and sodium chloride, ethylparaben add the hot water dissolving in addition, and mixing is regulated pH value.Water for injection is diluted to 1000ml, with the hollow-fibre membrane filtration in molecular cut off 30000 apertures, fill, sterilization, promptly.
8, according to claim 1 and described compound recipe eye drops with capillary artemisia, cape jasmine and baikal skullcap root of claim 6 and its preparation method, wherein, described nanometer film, be meant the various special-shaped membrane material and the equipment thereof of the preparation of macromolecular material such as polysulfones, the molecular cut off 10000-100000 of membrane aperture, the preferably molecular cut off 30000 and the equipment thereof of doughnut membrane aperture.
9, the eye drop of claim 1 is used in the medicine of preparation conjunctivitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100571874A CN100417399C (en) | 2006-03-14 | 2006-03-14 | Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100571874A CN100417399C (en) | 2006-03-14 | 2006-03-14 | Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1850191A true CN1850191A (en) | 2006-10-25 |
| CN100417399C CN100417399C (en) | 2008-09-10 |
Family
ID=37131703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100571874A Expired - Fee Related CN100417399C (en) | 2006-03-14 | 2006-03-14 | Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100417399C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836228A (en) * | 2012-10-10 | 2012-12-26 | 陈兴旺 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1554432A (en) * | 2003-12-27 | 2004-12-15 | 北京神农坛医药科技有限公司 | Yinzhihuang injection preparation and its preparing method |
-
2006
- 2006-03-14 CN CNB2006100571874A patent/CN100417399C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836228A (en) * | 2012-10-10 | 2012-12-26 | 陈兴旺 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
| CN102836228B (en) * | 2012-10-10 | 2014-06-25 | 滨州医学院附属医院 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100417399C (en) | 2008-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100348258C (en) | Medicine for treating upper respiratory tract infection and preparation method thereof | |
| CN1056751C (en) | Zhishiqingjie injection | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1965853A (en) | Application of gentiopicroside in preparation of antiviral medicament | |
| CN1285349C (en) | Chinese medicinal formulation for treating asthenopia syndrome and its preparation method | |
| CN1965877A (en) | Chinese medicinal eye drop for treating bacteria and virus infected conjunctivitis | |
| CN1293101C (en) | White fungus polysaccharide and its preparation method as well as medicament composition with the compound as active constituent | |
| CN1850191A (en) | Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method | |
| CN1273493C (en) | Angelica polysaccharide and its preparation and use | |
| CN1067258C (en) | Medicinal preparation with extractive from yangtao root and preparing process thereof | |
| CN1264529C (en) | Freeze-dried 'Shenqifuzheng' powder for injection and its preparing process | |
| CN1686464A (en) | Radix dactylicapni injection and its preparation method | |
| CN102389449B (en) | Erigeron breviscapus extract and preparation method and application thereof | |
| CN1872192A (en) | A medication composition,and preparation method | |
| CN100515469C (en) | Oral liquid for treating common cold heat | |
| CN1876044A (en) | A Chinese medicinal composition for treating infant fever caused by exogenous pathogen and preparation method thereof | |
| CN101301304A (en) | Chinese medicinal composition for treating ischemic stroke and preparation thereof | |
| CN1803155A (en) | Medicine for curing rhinitis | |
| CN1229132C (en) | Medicine for treating wind-heat type common cold and its prepn | |
| CN100339126C (en) | Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process | |
| CN1432391A (en) | Recipe of Chinese medicine with treating and health care functions | |
| CN1291738C (en) | Anti-phlogistic anti-viral medicine compositon and technique for preparing the same | |
| CN100336535C (en) | Children health pectoral mixture for treating child wind and heat caused by exopathogen and its preparing method | |
| CN1053817C (en) | Acanthopanax root injection freeze-dried powder injection and producing technology for acanthopanax root extract | |
| CN1251766A (en) | Qingyin injection for clearing heat and resisting infection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: Tianchuang Technology Building No. 8 Beijing road Haidian District Cai Dutch square room 720 Patentee after: Beijing Guodan Medicine Technology Development Co.,Ltd. Address before: No. 8, Gucheng West Road, Beijing, Shijingshan District Patentee before: Beijing Guodan Medicine Technology Development Co.,Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081212 Address after: No. 1, one heart road, Shuangyang Economic Development Zone, Changchun Patentee after: Jilin Yixin pharmaceutical Limited by Share Ltd. Address before: Tianchuang Technology Building No. 8 Beijing road Haidian District Cai Dutch square room 720 Patentee before: Beijing Guodan Medicine Technology Development Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: JILIN YIXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING GUO DAN DRUG TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20081212 |
|
| C56 | Change in the name or address of the patentee |
Owner name: JILIN A-THINK PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: JILIN YIXIN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 130616, No. 1, one heart road, Shuangyang Economic Development Zone, Changchun Patentee after: SINOPHARM A-THINK PHARMACEUTICAL Co.,Ltd. Address before: 130616, No. 1, one heart road, Shuangyang Economic Development Zone, Changchun Patentee before: Jilin Yixin pharmaceutical Limited by Share Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080910 |